Stem cell transplantation for induction of remission in medically refractory Crohn’s disease

El‐Nakeep, Sarah; Latif, Osama Abdel; Shawky, Ahmed M.; Nabhan, Ashraf

doi:10.1002/14651858.cd013070

Cited by 2 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary endpoint, aiming to show the benefit of HSCT, was not met, as only two patients after HSCT reached sustained disease remission compared to one patient in the standard treatment arm. This study was also the only one evaluating HSCT in CD included in a recent Cochrane review on stem cell transplantation in CD [ 54 ], as the other six included studies assessed mesenchymal stem cell transplantation for perianal fistulas. Except for a high risk of bias concerning the missing blinding of patients, clinicians, and investigators, the authors of this review judged the study to be at low risk of bias.…”

Section: Hsct For Crohn’s Diseasementioning

confidence: 99%

“…The ASTIC trial reported a higher rate of adverse events in the HSCT group compared to the control cohort within the first 100 days after conditioning and transplantation [ 45 ]. The earlier mentioned recent Cochrane Review about stem cell transplantation for CD did not find an increased risk of adverse events in patients undergoing transplantation, but an indication of an increase in serious adverse events, although certainty of evidence was reported to be low [ 54 ].…”

Section: Hsct For Crohn’s Diseasementioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?

Reider

Binder

Fürst

et al. 2022

Cells

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is widely used in benign and malignant hematological diseases. During the last decade, HSCT, mainly autologous, also gained increasing attention in the treatment of refractory autoimmune diseases. Crohn’s disease (CD) is an inflammatory bowel disease leading to transmural inflammation potentially affecting all parts of the luminal gastrointestinal tract. Despite improving therapeutic options, including various biologics, some patients are refractory to all lines of available conservative therapy, leading to increased morbidity and reduced quality of life. Apart from surgery, HSCT might be a reasonable treatment alternative for refractory CD patients. This review aims to describe the current role of HSCT in CD and discusses the procedure, the correct patient selection, the clinical efficacy from initial remission to following relapse rates, and complications of this treatment.

show abstract

Section: Hsct For Crohn’s Diseasementioning

confidence: 99%

Section: Hsct For Crohn’s Diseasementioning

confidence: 99%

Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?

Reider

Binder

Fürst

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes

El‐Nakeep

2022

CSCR

View full text Add to dashboard Cite

Background: Crohn's disease (CD) is an autoimmune disease of the gastrointestinal tract, characterized by relapsing and remitting courses. The disease is debilitating in nature with three prominent phenotypic clinical presentations; fistulizing, stenosing, and inflammatory. Stem cells offer a new hope for CD patients with modifying the immune response and progression of the healing process. Aim: This mini-review discusses the role of stem cells in treating CD, their effectiveness as a new therapy and their current limitations faced. Methods: The author conducted a literature review on recent randomized controlled trials and cohort studies concerned with the topic in question using the following keywords (Crohn's Disease, perianal fistula, Stem cell therapy, mesenchymal stem cells, remission). Results: Clinical trials show that the stem cells are more effective in the CD associated complex perianal fistula than the CD enteritis. Till the time being, there are no standardized guidelines regarding; dose of stem cells used, number of doses administered, route of administration, type of stem cells used. Only one group of researchers proposed a standardized procedure for injecting mesenchymal stem cells in complex perianal fistula, according to their own experience in clinical trials. Moreover, mesenchymal stem cells and their related types (placental, adipose tissue, umbilical tissue, etc.) are the most safe and effective in clinical trials. Currently; the commercially available mesenchymal stem cells preparation (Darvadstrocel (Cx601)) is the only one approved by The United States Food and Drug Administration (FDA) for clinical use in refractory CD associated complex perianal fistula. Conclusions: Stem cell therapy (SCT) shows promise in; inducing remission in refractory Crohn's colitis, and perianal fistula, but further research is required before SCT could be applied to clinical practice guidelines

show abstract

Stem cell transplantation for induction of remission in medically refractory Crohn’s disease

Cited by 2 publications

References 43 publications

Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?

Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?

Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes

Contact Info

Product

Resources

About